Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00324675|
Recruitment Status : Completed
First Posted : May 11, 2006
Results First Posted : October 21, 2011
Last Update Posted : November 2, 2011
To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.
Diabetic nephropathy is a world wide public health concern of increasing proportions. It has become the most common single cause of end-stage renal disease in the United States and in Europe. Previous studies have already found agents modifying the renin-angiotensin-system (ACE inhibitors and angiotensin receptor blocker) to retard diabetic nephropathy. These agents are likely to exert multiple effects in the kidney. One of them appear to be their known ability to improve endothelial function and to change renal glomerular hemodynamics.
In a previous study we demonstrated an improvement of renal endothelial dysfunction in type 2 diabetic patients without end organ damage after treatment with rosiglitazone. In that study, rosiglitazone significantly reduced glomerular hyperfiltration. This was associated with a reduction of urinary albumin excretion. The observed effects are potentially important in the context of renal protection, provided that a similar beneficial effect of rosiglitazone is demonstrable in overt diabetic nephropathy (renal insufficiency, hypertension, proteinuria).
Hypothesis Rosiglitazone decreases proteinuria and improves renal hemodynamic function in patients with chronic renal insufficiency due to overt diabetic nephropathy.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Overt Diabetic Nephropathy||Drug: Rosiglitazone Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy|
|Study Start Date :||August 2006|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2010|
|Active Comparator: Rosiglitazone||
4 mg tablets, bid, 12 months
|Placebo Comparator: placebo||
2 tablets per day
- Proteinuria [ Time Frame: at baseline and after 6 and 12 mo of treatment ]
- Renal Hemodynamic [ Time Frame: at baseline and after 6 and 12 mo of tretament ]
- Renal Function [ Time Frame: at abseline and after 6 and 12 mo ]
- Adverse Event [ Time Frame: every month or at occurence ]
- HbA1c [ Time Frame: at baseline and after 6 and 12 mo ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00324675
|University hospital Dresden|
|Dresden, Germany, 01307|
|Principal Investigator:||Frank Pistrosch, M.D.||Nephrology, Department of Medicine, University hospital Dresden|